ARWR EBITDA Growth
Arrowhead Pharmaceuticals Inc · EBITDA Growth
ARWR EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-154.58%period ending
ARWR TTM EBITDA YoY % (898.57% → -154.58%)
Year-over-year change
High-resolution chart · PNG
ARWR ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -154.5815% | |
| -97.3929% | |
| 163.7558% | |
| 129.3532% | |
| 89.6696% | |
| 84.4861% | |
| -116.2913% | |
| -219.6372% | |
| -223.7856% | |
| -233.9803% | |
| -91.8802% | |
| -6.8499% | |
| -7.7971% | |
| -23.9895% | |
| 21.9695% | |
| -16.7934% | |
| -14.8997% | |
| 4.7061% | |
| -69.4361% | |
| -61.4044% | |
| -350.2064% | |
| -1,999.332% | |
| -312.0251% | |
| -232.891% | |
| -162.6009% | |
| -44.8635% | |
| 288.7669% | |
| 228.0886% | |
| 189.2361% | |
| 126.4316% | |
| 15.4184% | |
| -58.6034% | |
| -19.6675% | |
| 28.3186% | |
| 56.339% | |
| 57.733% | |
| 48.5864% | |
| 28.6801% | |
| 18.0361% | |
| 18.3729% | |
| 8.1495% | |
| 8.9284% | |
| -28.5087% | |
| -88.1806% | |
| -138.1308% | |
| -191.2051% | |
| -185.9156% | |
| -131.1132% | |
| -98.5415% | |
| -43.8456% | |
| -18.191% | |
| -11.3214% | |
| -9.2966% | |
| -63.8421% | |
| -103.6064% | |
| -102.2553% | |
| -93.5505% | |
| -47.4076% | |
| -138.9255% | |
| -235.0443% | |
| -124.8942% | |
| -82.3272% | |
| 66.3582% | |
| 84.6513% | |
| 85.0725% | |
| 86.2922% | |
| 65.8271% | |
| 45.7566% | |
| 22.7065% | |
| 9.8395% | |
| 8.481% | |
| 7.2142% | |
| -0.7706% | |
| -50.0236% | |
| -72.3711% | |
| -64.6217% | |
| -116.3844% | |
| -78.8198% | |
| -130.7416% | |
| -196.5773% | |
| -119.7781% | |
| -176.2777% | |
| -139.768% | |
| -180.9582% | |
| -457.8129% | |
| -625.407% | |
| -1,949.2708% | |
| -2,915.0554% | |
| 7.3239% | |
| 50.2992% | |
| 85.7569% | |
| 93.6516% | |
| -1,038.7515% | |
| -1,416.7243% | |
| -1,388.7489% | |
| -1,277.5193% | |
| -23.6362% | |
| 10.2236% | |
| 8.6% | |
| -0.5285% |